HLA-A and melanoma: In case of CD8+ T cells, this approach has already been followed by Johnson et al., who cloned from CD8+ T cells of HLA-A*02-transgenic mice highly avid TCR recognizing the human melanoma differentiation antigen gp100, in order to generate recombinant human PBL for adoptive cellular therapy of melanoma patients [39].